<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="04/05/2006" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9756417" creator="Noriko Katsu">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>9756417</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term sem="Other" id="T1" lex="transcription_factor_activation"><term sem="Protein_family_or_group" id="T2" lex="transcription_factor">Transcription factor</term> activation</term> in <term sem="Protein_molecule" id="A1">lymphokine</term> activated <term sem="Cell_natural" id="T3" lex="killer_cell">killer cells</term> and <term sem="Cell_natural" id="T4" lex="lymphocyte">lymphocytes</term> from patients receiving <term sem="Other" id="T5" lex="IL-2_immunotherapy"><term sem="Protein_molecule" id="T6" lex="IL-2">IL-2</term> immunotherapy</term>.</sentence>
<event id="E1">
<type class="Positive_regulation" />
<theme idref="T2" />
<clue>Transcription factor <clueType>activation</clueType> <clueLoc>in lymphokine activated killer cells</clueLoc> and lymphocytes from patients receiving IL-2 immunotherapy.</clue>
</event>
<event id="E29">
<type class="Positive_regulation" />
<theme idref="T2" />
<clue>Transcription factor <clueType>activation</clueType> <clueLoc>in</clueLoc> lymphokine activated killer cells and <clueLoc>lymphocytes from patients receiving IL-2 immunotherapy</clueLoc>.</clue>
</event>
<event id="E2">
<type class="Physiological_process" />
<theme idref="T3" />
<cause idref="A1" />
<clue>Transcription factor activation in lymphokine <clueType>activated</clueType> killer cells and lymphocytes from patients receiving IL-2 immunotherapy.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Administration of the <term sem="Protein_molecule" id="T7" lex="cytokine_interleukin-2">cytokine interleukin-2</term> (<term sem="Protein_molecule" id="T8" lex="IL-2">IL-2</term>) can result in therapeutic benefits for individuals with <term sem="Tissue_natural" id="T9" lex="renal_cell_carcinoma">renal cell carcinoma</term> and <term sem="Other" id="T10" lex="melanoma">melanoma</term>.</sentence>
<event id="E3">
<type class="Artificial_process" />
<theme idref="T8" />
<clue><clueType>Administration</clueType> <linkTheme>of</linkTheme> the cytokine interleukin-2 (IL-2) can result in therapeutic benefits for individuals with renal cell carcinoma and melanoma.</clue>
</event>
<sentence id="S3">Here we report an analysis of the <term sem="Protein_family_or_group" id="T11" lex="transcription_factor_family">transcription factor families</term> <term sem="Protein_complex" id="T55" lex="AP-1">AP-1</term>, <term sem="Protein_molecule" id="T56" lex="SP1">Sp1</term>, <term sem="Protein_complex" id="T12" lex="NF-kappaB">NF-kappaB</term>, and <term sem="Protein_family_or_group" id="T13" lex="signal_transducers_and_activators_of_transcription">signal transducers and activators of transcription</term> (<term sem="Protein_family_or_group" id="T14" lex="STAT">STAT</term>) in <term sem="Cell_natural" id="T15" lex="cancer_patients&apos;_lymphocytes">cancer patients&apos; <term sem="Cell_natural" id="T16" lex="lymphocyte">lymphocytes</term></term> before and after <term sem="Other" id="T17" lex="IL-2_immunotherapy"><term sem="Protein_molecule" id="T18" lex="IL-2">IL-2</term> immunotherapy</term>, as assessed by a <term sem="Other" id="T19" lex="gel-shift_assay">gel-shift assay</term>.</sentence>
<sentence id="S4">An in vitro surrogate of <term sem="Other" id="T20" lex="IL-2_immunotherapy"><term sem="Protein_molecule" id="T21" lex="IL-2">IL-2</term> immunotherapy</term> is the incubation of <term sem="Cell_natural" id="T22" lex="fresh_peripheral_blood_mononuclear_cell">fresh peripheral blood mononuclear cells</term> (<term sem="Cell_natural" id="T23" lex="PBMC">PBMC</term>) from <term sem="Multicellular_organism_natural" id="T24" lex="healthy_individual">healthy individuals</term> in <term sem="Protein_molecule" id="T25" lex="IL-2">IL-2</term> for several days, resulting in the production of <term sem="Other" id="T26" lex="lymphokine-activated_killer_(LAK)_activity"><term sem="Protein_family_or_group" id="T27" lex="lymphokine">lymphokine</term>-activated <term sem="Cell_natural" id="A2">killer</term> (LAK) activity</term> in these cultures.</sentence>
<event id="E4">
<type class="Artificial_process" />
<theme idref="T23" />
<theme idref="T25" />
<clue>An in vitro surrogate of IL-2 immunotherapy is the <clueType>incubation</clueType> <linkTheme>of</linkTheme> fresh peripheral blood mononuclear cells (PBMC) from healthy individuals <linkTheme>in</linkTheme> IL-2 <clueTime>for several days</clueTime>, resulting in the production of lymphokine-activated killer (LAK) activity in these cultures.</clue>
</event>
<event id="E5">
<type class="Positive_regulation" />
<theme idref="E6" />
<cause idref="E4" />
<clue>An in vitro surrogate of IL-2 immunotherapy is the incubation of fresh peripheral blood mononuclear cells (PBMC) from healthy individuals in IL-2 for several days, <clueType>resulting in the production</clueType> <linkTheme>of</linkTheme> lymphokine-activated killer (LAK) activity <clueLoc>in these cultures</clueLoc>.</clue>
</event>
<event id="E6">
<type class="Physiological_process" />
<theme idref="A2" />
<cause idref="T27" />
<clue>An in vitro surrogate of IL-2 immunotherapy is the incubation of fresh peripheral blood mononuclear cells (PBMC) from healthy individuals in IL-2 for several days, resulting in the production of lymphokine-<clueType>activated</clueType> killer (LAK) activity in these cultures.</clue>
</event>
<sentence id="S5">One purpose of this study was to describe the profile of <term sem="Other" id="T28" lex="transcription_factor_activation"><term sem="Protein_family_or_group" id="A3">transcription factor</term> activation</term> in these different populations, and assess whether the patterns observed correlated with <term sem="Other" id="T29" lex="functional_difference">functional differences</term> in these cells.</sentence>
<event uncertainty="doubtful" id="E7">
<type class="Positive_regulation" />
<theme idref="A3" />
<clue>One purpose of this study was to describe the profile of transcription factor <clueType>activation</clueType> <clueLoc>in these different populations</clueLoc>, and assess whether the patterns observed correlated with functional differences in these cells.</clue>
</event>
<sentence id="S6">Prior to in vivo <term sem="Protein_molecule" id="T30" lex="IL-2">IL-2</term> administration, the typical binding pattern of <term sem="Protein_family_or_group" id="T31" lex="transcription_factor">transcription factors</term> in <term sem="Cell_natural" id="T32" lex="PBMC">PBMC</term> from patients resembled that seen in fresh <term sem="Cell_natural" id="T33" lex="PBMC">PBMC</term> from <term sem="Multicellular_organism_natural" id="T34" lex="healthy_individual">healthy individuals</term>.</sentence>
<event id="E8">
<type class="Artificial_process" />
<theme idref="T30" />
<clue>Prior to in vivo IL-2 <clueType>administration</clueType>, the typical binding pattern of transcription factors in PBMC from patients resembled that seen in fresh PBMC from healthy individuals.</clue>
<comment>NO THEME</comment>
</event>
<event id="E9">
<type class="Binding" />
<theme idref="T31" />
<clue><clueTime>Prior to in vivo IL-2 administration</clueTime>, the typical <clueType>binding</clueType> pattern <linkTheme>of</linkTheme> transcription factors <clueLoc>in PBMC from patients</clueLoc> resembled that seen in fresh PBMC from healthy individuals.</clue>
</event>
<event id="E10">
<type class="Binding" />
<theme idref="T31" />
<clue>Prior to in vivo IL-2 administration, the typical <clueType>binding</clueType> pattern <linkTheme>of</linkTheme> transcription factors in PBMC from patients resembled that seen <clueLoc>in fresh PBMC from healthy individuals</clueLoc>.</clue>
</event>
<sentence id="S7">Over a 3-week course of <term sem="Protein_molecule" id="T35" lex="IL-2">IL-2</term> therapy, in most <term sem="Multicellular_organism_natural" id="T36" lex="patient">patients</term> the binding patterns of <term sem="Protein_molecule" id="T37" lex="AP-1">AP-1</term> , <term sem="Protein_molecule" id="T38" lex="Sp1">Sp1</term>, and <term sem="Protein_complex" id="T39" lex="NF-kappaB">NF-kappaB</term> proteins changed to resemble those seen in <term sem="Cell_natural" id="T40" lex="PBMC">PBMC</term> activated by <term sem="Protein_molecule" id="T41" lex="IL-2">IL-2</term> in vitro.</sentence>
<event id="E11">
<type class="Positive_regulation" />
<theme idref="E14" />
<cause idref="T35" />
<clue><clueTime>Over a 3-week course</clueTime> <linkCause>of</linkCause> IL-2 therapy, in most patients the binding patterns of AP-1 , Sp1, and NF-kappaB proteins <clueType>changed</clueType> to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event id="E12">
<type class="Positive_regulation" />
<theme idref="E15" />
<cause idref="T35" />
<clue><clueTime>Over a 3-week course</clueTime> <linkCause>of</linkCause> IL-2 therapy, in most patients the binding patterns of AP-1 , Sp1, and NF-kappaB proteins <clueType>changed</clueType> to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event id="E13">
<type class="Positive_regulation" />
<theme idref="E16" />
<cause idref="T35" />
<clue><clueTime>Over a 3-week course</clueTime> <linkCause>of</linkCause> IL-2 therapy, in most patients the binding patterns of AP-1 , Sp1, and NF-kappaB proteins <clueType>changed</clueType> to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event id="E14">
<type class="Binding" />
<theme idref="T37" />
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event id="E15">
<type class="Binding" />
<theme idref="T38" />
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event id="E16">
<type class="Binding" />
<theme idref="T39" />
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event id="E17">
<type class="Binding" />
<theme idref="T37" />
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen <clueLoc>in PBMC activated by IL-2 in vitro</clueLoc>.</clue>
</event>
<event id="E18">
<type class="Binding" />
<theme idref="T38" />
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen <clueLoc>in PBMC activated by IL-2 in vitro</clueLoc>.</clue>
</event>
<event id="E19">
<type class="Binding" />
<theme idref="T39" />
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen <clueLoc>in PBMC activated by IL-2 in vitro</clueLoc>.</clue>
</event>
<event id="E20">
<type class="Physiological_process" />
<theme idref="T40" />
<cause idref="T41" />
<clue>Over a 3-week course of IL-2 therapy, in most patients the binding patterns of AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen in PBMC <clueType>activated</clueType> <linkCause>by</linkCause> IL-2 in vitro.</clue>
</event>
<sentence id="S8">However, the cells obtained from <term sem="Other" id="T42" lex="IL-2-treated_patient"><term sem="Protein_molecule" id="T43" lex="IL-2">IL-2</term>-treated <term sem="Multicellular_organism_natural" id="T44" lex="patient">patients</term></term> did not have low-level constitutive expression of <term sem="Protein_family_or_group" id="T45" lex="STAT_binding_factor">STAT binding factors</term> as did <term sem="Protein_family_or_group" id="T46" lex="LAK_cell">LAK cells</term>.</sentence>
<event assertion="non-exist" id="E21">
<type class="Gene_expression" />
<theme idref="T45" />
<clue>However, <clueLoc>the cells obtained from IL-2-treated patients</clueLoc> did not have low-level constitutive <clueType>expression</clueType> <linkTheme>of</linkTheme> STAT binding factors as did LAK cells.</clue>
</event>
<event id="E23">
<type class="Gene_expression" />
<theme idref="T45" />
<clue>However, the cells obtained from IL-2-treated patients did not have low-level constitutive <clueType>expression</clueType> <linkTheme>of</linkTheme> STAT binding factors as did <clueLoc>LAK cells</clueLoc>.</clue>
<comment>CAUTION: SEE</comment>
</event>
<sentence id="S9">When these patient cells were further stimulated by <term sem="Other" id="T47" lex="IL-2_in_vitro"><term sem="Protein_molecule" id="T48" lex="IL-2">IL-2</term> in vitro</term>, additional differences in <term sem="Other" id="T49" lex="STAT_induction"><term sem="Protein_family_or_group" id="T50" lex="STAT">STAT</term> induction</term> patterns were noted.</sentence>
<event id="E24">
<type class="Physiological_process" />
<theme idref="T40" />
<cause idref="T48" />
<clue>When <corefTheme>these patient cells</corefTheme> were further <clueType>stimulated</clueType> <linkCause>by</linkCause> IL-2 in vitro, additional differences in STAT induction patterns were noted.</clue>
</event>
<event id="E25">
<type class="Positive_regulation" />
<theme idref="T50" />
<clue>When these patient cells were further stimulated by IL-2 in vitro, additional differences in STAT <clueType>induction</clueType> patterns were noted.</clue>
<comment>NER: T49 mod</comment>
</event>
<sentence id="S10">These data provide further information on the <term sem="Other" id="A4">molecular events</term> occurring in <term sem="Cell_natural" id="T51" lex="immune_cell">immune cells</term> generated through in vivo and in vitro administration of <term sem="Protein_molecule" id="T52" lex="IL-2">IL-2</term>, and further document that there is not a precise congruence between <term sem="Cell_natural" id="T53" lex="PBMC">PBMC</term> activated in vivo and in vitro by <term sem="Protein_molecule" id="T54" lex="IL-2">IL-2</term>.</sentence>
<event id="E26">
<type class="Artificial_process" />
<theme idref="T52" />
<clue>These data provide further information on the molecular events occurring in immune cells generated through in vivo and in vitro <clueType>administration</clueType> <linkCause>of</linkCause> IL-2, and further document that there is not a precise congruence between PBMC activated in vivo and in vitro by IL-2.</clue>
</event>
<event id="E27">
<type class="Positive_regulation" />
<theme idref="A4" />
<cause idref="E26" />
<clue>These data provide further information on the molecular events <clueType>occurring</clueType> <clueLoc>in immune cells</clueLoc> <linkCause>generated through</linkCause> in vivo and in vitro administration of IL-2, and further document that there is not a precise congruence between PBMC activated in vivo and in vitro by IL-2.</clue>
</event>
<event id="E28">
<type class="Physiological_process" />
<theme idref="T53" />
<cause idref="T54" />
<clue>These data provide further information on the molecular events occurring in immune cells generated through in vivo and in vitro administration of IL-2, and further document that there is not a precise congruence between PBMC <clueType>activated</clueType> in vivo and in vitro <linkCause>by</linkCause> IL-2.</clue>
</event>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
